Slide 1: Coffee Microcaps – Steven Lydeamore, CEO
7 March 2025 Steven Lydeamore Chief Executive Officer Coffee Microcaps NASDAQ: IMRN ASX: IMC
Slide 2: Safe Harbor Statement
Certain statements made in this presentation are forward - looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “ anticipates,” “expects,” “intends,” “plans,” “believes,” “ seeks,” “estimates,” “guidance” and s imilar expressions are intended t
Slide 3: Executive summary
3 Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases 3 as of 5 March 2025 IMM - 529 Immuron completes pre - IND meeting with FDA on the
Slide 4: Australian integrated biopharmaceutical company with global scale
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral immunotherapeutic for the treatment of gut mediated diseases Immuron Limited Vancouver, BC Canada Immuron Inc New York USA Immuron HQ Melbourne Australia Research & D
Slide 5: Travellers' Diarrhoea: Facts
TRAVELLERS DIARRHOEA: FACTS Travellers’ Diarrhoea – What is it? • Travellers’ Diarrhoea is more commonly referred to as Bali Belly, Delhi Belly, Montezuma’s Revenge, Tourist Trot, Rangoon Runs or just TD. • Characterised by fever, belly cramps and profuse watery diarrhoea that can last for several d
Slide 6: Travel statistics
Travel statistics: • Statistics show that diarrhea and symptoms associated with gastrointestinal disorders is one of the leading travel health problems, affecting up to 70% of travelers (in medium to high risk area’s) • Travellers Diarrhoea frequently occurs in environments where there is poor or no
Slide 7: Opportunity to convert billion dollar traveller's diarrhoea market from relief to prevention
7 Opportunity to Convert Billion Dollar Traveller’s Diarrhoea Market from Relief to Prevention by Travelan® Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% 1 Industry tailwinds International travel continues to grow Travel to high - risk destination
Slide 8: Continued strong sales growth
CONTINUED STRONG SALES GROWTH o Global sales increased by 172% in the 2024 fiscal year to a record A$4.9 million compared to A$1.8 million in FY23 o Half Yearly sales record in Dec 24 A$4.0 million, up 70% pcp o Australia o FY24: a record A$3.75 million; up 223% o Half Yearly sales in December 2024
Slide 9: Expansion of Travelan distribution
EXPANSION OF TRAVELAN® DISTRIBUTION
Slide 10: Strong pipeline with near term milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES 10 2H 2025 1H 2025 Current Status Collaborator Registration Phase 3 Phase 2 Phase 1 Preclinical Peak U.S. sales Compound Indication Topline Data Recruitment Completed 100% of 866 participants recruited Uniformed Services University US$ 102 m Travelan® Travel
Slide 11: Scientific references
11 Scientific references Travelan® (IMM - 124E) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health System Research Sy
Slide 12: Contact information
EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: